This article describes the underlying methods, validation and example applications of the most recent models of Cytochrome P450 metabolism in StarDrop’s P450 module.
Summary
Cytochrome P450s (CYPs) are one of the most important enzyme families involved in drug metabolism. To ensure metabolic stability, reduce the risk of drug-drug interactions and evaluate potential metabolites, it is essential to predict whether and at which atomic sites CYP will metabolise your compound.
In this article, a method for predicting CYP metabolism is introduced. It considers two factors. Firstly, reactivity of each site to metabolism in the context of the molecule is calculated, via semi-empirical quantum mechanical simulations. Secondly, isoform-specific accessibility is considered, using ligand-based models to correct for steric and orientation effects which differ between CYP isoform binding pockets. The resulting models can accurately predict both the relative proportion of metabolite formation and provide an estimation of the activation energy of each site.
Citation details
J. D. Tyzack, P. A. Hunt, and M. D. Segall, J. Chem. Inf. Model. 2016, 56, 11, 2180–2193
Find out more
You can read the published article on the journal webpage via the button below.
Alternatively, for more information on our metabolism research, check out some of the following links:
- Peer-reviewed article: WhichP450: a multi-class categorical model
-
Peer-reviewed article: Predicting Regioselectivity of Cytosolic SULT Metabolism for Drugs
-
Poster: Predicting Reactivity to Drug Metabolism: Beyond CYPs
- Webinar: Integrated prediction of phase I and II metabolism
INTERESTED IN PREDICTIVE MODELS?
Discover StarDrop™
With its comprehensive suite of integrated software, StarDrop™ delivers best-in-class in silico technologies within a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through predictive modelling to decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the drug optimisation and discovery process.